Significance of thymidylate synthase activity in renal cell carcinoma

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1453-1460

  Mizutani, Yoichi ^a   Wada, Hiromi ^b   Yoshida, Osamu ^b   Fukushima, Masakazu ^c   Nonomura, Mitsuo ^d   Nakao, Masahiro ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

^d KYOTO KATSURA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; FLOXURIDINE PHOSPHATE; FLUOROURACIL; PYRIMIDINE NUCLEOTIDE; TETRAZOLIUM; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BINDING ASSAY; CANCER GROWTH; CANCER SURVIVAL; CATALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DNA SYNTHESIS; DRUG DEGRADATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELLS, CULTURED; COLORING AGENTS; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN BINDING; PYRIMIDINES; TETRAZOLIUM SALTS; THIAZOLES; THYMIDYLATE SYNTHASE; TIME FACTORS;

EID: 0037386872     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Danenberg, P. V. Thymidylate synthase: a target enzyme in cancer chemotherapy. Biochem. Biophys. Acta., 473: 73-92, 1977.
2. Bukowski, R. M. Natural history and therapy of metastatic renal cell carcinoma. Cancer (Phila.), 80: 1198-1220, 1997.
3. Negrier, S., Caty, A., Lesimple, T., Douillard, J. Y., Escudier, B., Rossi, J. F., Viens, P., and Gomez, F. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon α with or without fluorouracil. J. Clin. Oncol., 18: 4009-4015, 2000.
4. Pinedo, H. M., and Peters, G. J. 5-Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., 6: 1653-1664. 1988.
5. Santi, D. V., McHenry, C. S., and Sommer, H. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridine. Biochemistry, 13: 471-480, 1974.
6. Pestalozzi, B. C., Peterson, H. F., Gelber, R. D., Goldhirsch, A., Gusterson, B. A., Trihia, H., Lindtner, J., Cortes-Funes, H., Simmoncini, E., Byrne, M. J., Golouh, R., Rudenstam, C. M., Castiglione-Gertsch, M., Allegra, C. J., and Johnston, P. G. Prognostic importance of thymidylate synthase expression in early breast cancer. J. Clin. Oncol., 15: 1923-1931, 1997.
7. Foekens, J. A., Romain, S., Look, M. P., Martin, P. M., and Klijn, J. G. M. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res., 61: 1421-1425, 2001.
8. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
9. Lu, Z., Zhang, R., and Diasio, R. B. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J. Biol. Chem., 267: 17102-17109, 1992.
10. Yokota, H., Fernandez-Salguero, P., Furuya, H., Lin, K., McBride, O. W., Podschun, B., Schnackerz, K. D., and Gonzalez, F. J. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem., 269: 23192-23196, 1994.
11. Mizutani, Y., Wada, H., Yoshida. O., Fukushima, M., Nakanishi, H., Nakao, M., and Miki, T. Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. Eur. J. Cancer, 39: 541-547, 2003.
12. Diasio, R. B., and Lu, Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J. Clin. Oncol., 12: 2239-2242, 1994.
13. Heggie, G. D., Sommadossi, J. P., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
14. Harris, B. E., Song, R., Soong, S., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
15. Fleming, R. A., Milamo, G., Thyss, A., Etienne, M. C., Renee, N., Schneider, M., and Demard, F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res., 52: 2899-2902, 1992.
16. Mizutani, Y., Wada, H., Fukushima, M., Yoshida, O., Ukimura, O., Kawauchi, A., and Miki, T. Significance of dihydropyrimidine dehydrogenase activity in bladder cancer. Eur. J. Cancer, 37: 569-575, 2001.
17. Mizutani, Y., Wada, H., Ogawa, O., Yoshida, O., Fukushima, M., Nonomura, N., and Miki, T. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer (Phila.), 92: 510-518, 2001.
18. Wu, X. X., Mizutani, Y., Kakehi, Y., Yoshida, O., and Ogawa, O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res., 60: 2912-2918, 2000.
19. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y., and Yoshida, O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res., 55: 590-596, 1995.
20. Spears, C. P., Shahinian, A. H., Moran, R. G., Heidelberger, C., and Corbett, T. H. In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinoma. Cancer Res., 42: 450-456, 1982.
21. Mizutani, Y., Yoshida, O., Miki, T., and Bonavida, B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin. Cancer Res., 5: 2605-2612, 1999.
22. Mizutani, Y., Okada, Y., Fukumoto, M., Bonavida, B., and Yoshida, O. Doxorubicin sensitizes human bladder cancer cells to Fasmediated cytotoxicity. Cancer (Phila.), 79: 1180-1189, 1997.
23. Moch, H., Gasser, T., Amin, M. B., Torhorst, J., Sauter, G., and Mihatsch, M. J. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. Cancer (Phila.), 89: 604-614, 2000.
24. Chow, G. K., Myles, J., and Novick, A. C. The Cleveland Clinic experience with papillary (chromophil) renal cell carcinoma: clinical outcome with histopathological correlation. Can. J. Urol., 8: 1223-1228, 2001.
25. Hashimoto, Y., Shiotani, T., Eble, J. N., Glover, J. L., and Weber, G. Increased thymidylate synthase (EC 2.1.1.45) activity in normal and neoplastic proliferation. Cancer Biochem. Biophys., 10: 1-10, 1988.
26. Navalgund, L. G., Rossano, C., and Muench, A. J. Cell cycle regulation of thymidylate synthase gene expression in cultured mouse fibroblasts. J. Biol. Chem., 255: 7386-7390, 1980.
27. Chu, E., Voeller, D. M., and Jones, K. L. Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells. Mol. Cell. Biol., 14: 207-213. 1994.
28. Johnston, P. G., Drake. J. C., and Trepel, J. Immunological quantification of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil sensitive and resistant human cancer cell lines. Cancer Res., 52: 4306-4312, 1992.
29. Van der Wilt, C. L., Pinedo, H. M., and Smid, K. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res., 52: 2922-2928, 1992.
30. Lenz, H. J., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Groshen, S., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li, J., and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol., 14: 176-182, 1995.